Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-resistant Recurrent Ovarian Cancer 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 16Carboplatin 15Bevacizumab 7Hyperthermic Intraperitoneal Chemotherapy 5Cisplatin 4Taxes 3Gemcitabine 3Cytoreduction Surgical Procedures 3Chemotherapy, Adjuvant 3oregovomab 2niraparib 2fluzoparib 2Topotecan 2ST 1481 2Neoadjuvant Therapy 2Methods 2Immunohistochemistry 2Ifosfamide 2Gene Expression Profiling 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Amplified Fragment Length Polymorphism Analysis 2rucaparib 1pembrolizumab 1paclitaxel poliglumex 1olaparib 1navicixizumab 1mirvetuximab soravtansine 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Fallopian Tube Neoplasms × 1-dodecylpyridoxal × Clear all
NCT04983550 2021-07-30

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
126 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡